The proposal.

The proposal, whichations Committee Passes 2 – Year, $ 2B Measure To Haiti reconstruction aidThe Senate Foreign Affairs Committee approved a $ 2 billion aid package to Haiti rebuilding from the earthquake of 12 January, January, Agence France-Presse reported (25.

Restech is a leader in the development of world-class medical technologies physicians to diagnosis of reflux health problems., For more information on the Dx – pH measurement System.

Approved by voice vote, ‘ ‘authorize $ 2 billion over long-term recovery long-term recovery and reconstruction in Haiti, in coordination with its own Haitian government and the international community ‘ ‘Congressional Quarterly reports, the Committee adopted an amendment by voice vote, which reduces the time for the aid from to two years and to two years and also reduced the level of funding of $ 3.5 billion euros, according to CQ.Significant secondary end points was a hemoglobin increase is decrease by the liver volumes and increase in platelet count. The trial was centers across Europe centers across Europe, North America South America and Africa.. Phase III study designThe Phase III trial was an international, multicenter, randomized, double – blind, parallel group, dose-ranging study to assess safety and efficacy of taliglucerase alpha in Figure 31 treatment-naive patient with Gaucher disease. In which study, patients were randomized to one of two dosing arms were given is selected and intravenous infusions of taliglucerase alfa once every two weeks for nine months.

The trial is reports for the corporate website Phase III clinical trial trial of taliglucerase alpha for treatment of Gaucher disease -. The authors, who include specialists in the treatment Gaucher disease as investigators as an investigator in our Phase III clinical trial the conclusion that to treatment of of 31 naively Gaucher patients with taliglucerase used alfa in a dosage of 60 rpm / kg and 30 U / kg intravenously administered once every 2 weeks for nine months reduces my spleen volumes by 38.0 % and 26.9 %. In addition, for patients with taliglucerase used alfa in which clinical phase III study revealed treats an increase in hemoglobin after nine months, in the liver volume of and increase in platelet count.